Market Place
Sourcing Support
Genprex Receives Approval to Advance Reqorsa® Gene Therapy Trial
16 Dec 2024 //
PR NEWSWIRE
Genprex to Present Positive Preclinical Reqorsa® Data at SITC 2024
05 Nov 2024 //
PR NEWSWIRE
Genprex Receives Approval To Advance In Acclaim-3 Trial
15 Oct 2024 //
PR NEWSWIRE
Genprex To Present Reqorsa Data At EORTC-NCI-AACR Symposium
10 Oct 2024 //
PR NEWSWIRE
Genprex Plans to Launch New Company for Gene Therapy in Type-1 and 2 Diabetes
04 Sep 2024 //
PR NEWSWIRE
Vimgreen Completes Enrollment For Parkinson`s Disease Phase 2 Trial
15 Aug 2024 //
PR NEWSWIRE
Genprex Announces Positive Updates From Acclaim-1 And Acclaim-3 Trials
14 Aug 2024 //
PR NEWSWIRE
Genprex Gets Singapore Patent For Reqorsa With PD-1 Antibodies
13 Aug 2024 //
PR NEWSWIRE
Genprex Appoints Jose A. Moreno Toscano As Board Chairman
13 May 2024 //
PR NEWSWIRE
Genprex ExpandsTrial Sites for Acclaim-3 Study with Tecentriq to Treat SCLC
03 Apr 2024 //
PR NEWSWIRE
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy
02 Apr 2024 //
PR NEWSWIRE
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa
12 Mar 2024 //
PR NEWSWIRE
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
31 Jan 2024 //
PR NEWSWIRE
Genprex Provides Business Update and Outlook for 2024
05 Jan 2024 //
PR NEWSWIRE
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers
04 Oct 2023 //
PR NEWSWIRE
Genprex Receives Orphan Drug Designation for Immunogene Therapy for SCLC
21 Sep 2023 //
GLOBENEWSWIRE
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President
22 Aug 2023 //
PR NEWSWIRE
Genprex Granted FDA OD) for REQORSA® Immunogene Therapy
10 Aug 2023 //
PR NEWSWIRE
Genprex Signs License to Diabetes Technology with University of Pittsburgh
18 Jul 2023 //
PR NEWSWIRE
Genprex Receives Fast Track Designation From The FDA For Its ES-SCLC candidate
11 Jul 2023 //
ACCESSWIRE
Genprex Granted Chinese Patent for REQORSA Immunogene Therapy
05 Jul 2023 //
PR NEWSWIRE
Genprex Receives U.S. FDA Fast Track Designation for REQORSA
28 Jun 2023 //
PR NEWSWIRE
Genprex advances to Phase II expansion portion of Acclaim-1 trial
31 May 2023 //
CLINICAL TRIALS ARENA
Genprex Receives Safety Review Committee Approval to Advance to Ph2 Expansion
30 May 2023 //
PR NEWSWIRE
Genprex Publishes Positive Data from Phase 1 Trial Evaluating REQORSA
25 May 2023 //
PR NEWSWIRE
Genprex Unveils Video Featuring CMO Discussing Positive Data With NPRL2
23 May 2023 //
PR NEWSWIRE
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy
19 Apr 2023 //
PR NEWSWIRE
Independent Researchers Find TUSC2, the Gene Delivered by Genprex`s REQORSA
18 Apr 2023 //
PR NEWSWIRE
Genprex to Present at Bioprocessing Summit Conference
13 Mar 2023 //
PR NEWSWIRE
Genprex Announces Data Evaluating Novel Gene Therapy to Treat Type 1 Diabetes
23 Feb 2023 //
PR NEWSWIRE
Genprex Signs Exclusive License to Additional Diabetes Technology
05 Jan 2023 //
PR NEWSWIRE
Genprex Announces Selection of Preclinical Data for Presentation at ATTD 2023
04 Jan 2023 //
PR NEWSWIRE
Genprex Strengthens Therapy Program with License from University of Pittsburgh
15 Dec 2022 //
PRNEWSWIRE
Genprex Receives Approval to Proceed PI Trial of REQORSA with Tagrisso
14 Dec 2022 //
PRNEWSWIRE
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
16 Aug 2022 //
CLINICALTRIALSARENA
Genprex pairs gene therapy delivery tech with Keytruda in trial
06 Apr 2022 //
FIERCEPHARMA
Genprex Begins Dosing in Phase 1/2 Acclaim-1 Trial of REQORSA Immunogene Therapy
02 Mar 2022 //
BUSINESSWIRE
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX in Colon Cancer
27 Jan 2022 //
BUSINESSWIRE
Genprex Receives FDA FTD for REQORSA Immunogene Therapy + Keytruda in NSCLC
03 Jan 2022 //
BUSINESSWIRE
Genprex Announces Start of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™
23 Jun 2021 //
BUSINESSWIRE
Genprex In-Licenses Additional Gene Therapy Technologies for of Lung Cancer
06 May 2021 //
BUSINESSWIRE
Genprex In-Licenses Additional Gene Therapy Technologies
06 May 2021 //
BUSINESSWIRE
Genprex Announces Centralized Institutional Review Board Approval
05 May 2021 //
PRESS RELEASE
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene
13 Apr 2021 //
BUSINESSWIRE
Genprex Collaborators Report Positive Preclinical Data for REQORSA™
13 Apr 2021 //
BIOSACE
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy
30 Mar 2021 //
BUSINESSWIRE
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy
30 Mar 2021 //
BUSINESSWIRE
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow
21 Jan 2021 //
BUSINESSWIRE
Genprex Achieves Major Manufacturing Milestone for REQORSA™
13 Jan 2021 //
BIOSPACE
Genprex Completes Manufacturing Scale-Up for Clinical-Grade of REQORSA™
22 Dec 2020 //
BIOSPACE
Genprex Completes Manufacturing Scale-Up for Clinical-Grade of REQORSA™
22 Dec 2020 //
BIOSPACE
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
08 Dec 2020 //
BUSINESSWIRE
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
08 Dec 2020 //
BUSINESSWIRE
Genprex completes tech transfer for gene therapy to manufacturing
08 Dec 2020 //
SCIENCEBOARD
Genprex to Present at the Benzinga Global Small Cap Conference on December 8
03 Dec 2020 //
BUSINESSWIRE
Genprex Unveils New Branding for Upcoming Combination Clinical Trials
30 Oct 2020 //
BUSINESSWIRE
Genprex Unveils New Branding for Upcoming Combination Clinical Trials in NSCLC
30 Oct 2020 //
BUSINESSWIRE
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™
29 Oct 2020 //
GENPREX
Genprex to Present at Zooming with LD Micro on October 14, 2020
07 Oct 2020 //
BUSINESSWIRE
Genprex to Present at the ARM’s Virtual Cell and Gene Meeting on the Mesa
06 Oct 2020 //
BUSINESSWIRE
